Header Logo

Connection

CLIONA ROONEY to Mice

Back to Details
This is a "connection" page, showing publications CLIONA ROONEY has written about Mice.
CLIONA ROONEY
Connection Strength
0.887
Mice
  1. Cotargeting EBV lytic as well as latent cycle antigens increases T-cell potency against lymphoma. Blood Adv. 2024 07 09; 8(13):3360-3371.
    View in: PubMed
    Score: 0.071
  2. Constitutive Interleukin-7 Cytokine Signaling Enhances the Persistence of Epstein-Barr Virus-Specific T-Cells. Int J Mol Sci. 2023 Oct 31; 24(21).
    View in: PubMed
    Score: 0.068
  3. Naive T cells inhibit the outgrowth of intractable antigen-activated memory T cells: implications for T-cell immunotherapy. J Immunother Cancer. 2023 04; 11(4).
    View in: PubMed
    Score: 0.065
  4. A Costimulatory CAR Improves TCR-based Cancer Immunotherapy. Cancer Immunol Res. 2022 04 01; 10(4):512-524.
    View in: PubMed
    Score: 0.061
  5. A strategy to protect off-the-shelf cell therapy products using virus-specific T-cells engineered to eliminate alloreactive T-cells. J Transl Med. 2019 07 24; 17(1):240.
    View in: PubMed
    Score: 0.051
  6. NK Cells Expressing a Chimeric Activating Receptor Eliminate MDSCs and Rescue Impaired CAR-T Cell Activity against Solid Tumors. Cancer Immunol Res. 2019 03; 7(3):363-375.
    View in: PubMed
    Score: 0.049
  7. Constitutive Signaling from an Engineered IL7 Receptor Promotes Durable Tumor Elimination by Tumor-Redirected T Cells. Cancer Discov. 2017 11; 7(11):1238-1247.
    View in: PubMed
    Score: 0.044
  8. Vaccination Targeting Native Receptors to Enhance the Function and Proliferation of Chimeric Antigen Receptor (CAR)-Modified T Cells. Clin Cancer Res. 2017 Jul 15; 23(14):3499-3509.
    View in: PubMed
    Score: 0.043
  9. Combining mTor inhibitors with rapamycin-resistant T cells: a two-pronged approach to tumor elimination. Mol Ther. 2011 Dec; 19(12):2239-48.
    View in: PubMed
    Score: 0.029
  10. PiggyBac-mediated cancer immunotherapy using EBV-specific cytotoxic T-cells expressing HER2-specific chimeric antigen receptor. Mol Ther. 2011 Dec; 19(12):2133-43.
    View in: PubMed
    Score: 0.029
  11. Enhancement of dendritic cells as vaccines for cancer. Immunotherapy. 2010 Nov; 2(6):847-62.
    View in: PubMed
    Score: 0.028
  12. IRAK-M removal counteracts dendritic cell vaccine deficits in migration and longevity. J Immunol. 2010 Oct 01; 185(7):4223-32.
    View in: PubMed
    Score: 0.027
  13. In vivo fluorescent optical imaging of cytotoxic T lymphocyte migration using IRDye800CW near-infrared dye. Appl Opt. 2008 Nov 01; 47(31):5944-52.
    View in: PubMed
    Score: 0.024
  14. Hitchhiker's guide to the T cell. Nat Med. 2005 Oct; 11(10):1051-2.
    View in: PubMed
    Score: 0.019
  15. Conserved CTL epitopes on the adenovirus hexon protein expand subgroup cross-reactive and subgroup-specific CD8+ T cells. Blood. 2004 Oct 15; 104(8):2432-40.
    View in: PubMed
    Score: 0.018
  16. Novel OX40 and 4-1BB derived spacers enhance CD30 CAR activity and safety in CD30 positive lymphoma models. Mol Ther. 2024 Oct 02; 32(10):3504-3521.
    View in: PubMed
    Score: 0.018
  17. Epstein Barr virus-positive B-cell lymphoma is highly vulnerable to MDM2 inhibitors in vivo. Blood Adv. 2022 02 08; 6(3):891-901.
    View in: PubMed
    Score: 0.015
  18. Transposon-modified antigen-specific T lymphocytes for sustained therapeutic protein delivery in vivo. Nat Commun. 2018 04 10; 9(1):1325.
    View in: PubMed
    Score: 0.012
  19. Tonic 4-1BB Costimulation in Chimeric Antigen Receptors Impedes T Cell Survival and Is Vector-Dependent. Cell Rep. 2017 Oct 03; 21(1):17-26.
    View in: PubMed
    Score: 0.011
  20. Treatment of Acute Myeloid Leukemia with T Cells Expressing Chimeric Antigen Receptors Directed to C-type Lectin-like Molecule 1. Mol Ther. 2017 09 06; 25(9):2202-2213.
    View in: PubMed
    Score: 0.011
  21. Improving Chimeric Antigen Receptor-Modified T Cell Function by Reversing the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer. Mol Ther. 2017 01 04; 25(1):249-258.
    View in: PubMed
    Score: 0.011
  22. Highly Efficient Genome Editing of Murine and Human Hematopoietic Progenitor Cells by CRISPR/Cas9. Cell Rep. 2016 10 25; 17(5):1453-1461.
    View in: PubMed
    Score: 0.010
  23. Anti-Tumor Effects after Adoptive Transfer of IL-12 Transposon-Modified Murine Splenocytes in the OT-I-Melanoma Mouse Model. PLoS One. 2015; 10(10):e0140744.
    View in: PubMed
    Score: 0.010
  24. Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs. Blood. 2015 Jun 18; 125(25):3905-16.
    View in: PubMed
    Score: 0.009
  25. Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15. Blood. 2014 Jun 12; 123(24):3750-9.
    View in: PubMed
    Score: 0.009
  26. Kinetics of tumor destruction by chimeric antigen receptor-modified T cells. Mol Ther. 2014 Mar; 22(3):623-633.
    View in: PubMed
    Score: 0.009
  27. Robust T cell responses to aspergillosis in chronic granulomatous disease: implications for immunotherapy. Clin Exp Immunol. 2013 Oct; 174(1):89-96.
    View in: PubMed
    Score: 0.008
  28. Robust and cost effective expansion of human regulatory T cells highly functional in a xenograft model of graft-versus-host disease. Haematologica. 2013 Apr; 98(4):533-7.
    View in: PubMed
    Score: 0.008
  29. EBNA3B-deficient EBV promotes B cell lymphomagenesis in humanized mice and is found in human tumors. J Clin Invest. 2012 Apr; 122(4):1487-502.
    View in: PubMed
    Score: 0.008
  30. A Th1-inducing adenoviral vaccine for boosting adoptively transferred T cells. Mol Ther. 2011 Jan; 19(1):211-7.
    View in: PubMed
    Score: 0.007
  31. Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b. J Immunother. 2010 Oct; 33(8):780-8.
    View in: PubMed
    Score: 0.007
  32. An inducible caspase 9 suicide gene to improve the safety of mesenchymal stromal cell therapies. Stem Cells. 2010 Jun; 28(6):1107-15.
    View in: PubMed
    Score: 0.007
  33. Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety. Leukemia. 2010 Jun; 24(6):1160-70.
    View in: PubMed
    Score: 0.007
  34. Generation of Epstein-Barr virus-specific cytotoxic T lymphocytes resistant to the immunosuppressive drug tacrolimus (FK506). Blood. 2009 Nov 26; 114(23):4784-91.
    View in: PubMed
    Score: 0.006
  35. Immunotherapy for osteosarcoma: genetic modification of T cells overcomes low levels of tumor antigen expression. Mol Ther. 2009 Oct; 17(10):1779-87.
    View in: PubMed
    Score: 0.006
  36. T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. Blood. 2009 Jun 18; 113(25):6392-402.
    View in: PubMed
    Score: 0.006
  37. Genetic manipulation of tumor-specific cytotoxic T lymphocytes to restore responsiveness to IL-7. Mol Ther. 2009 May; 17(5):880-8.
    View in: PubMed
    Score: 0.006
  38. Antitumor activity of EBV-specific T lymphocytes transduced with a dominant negative TGF-beta receptor. J Immunother. 2008 Jun; 31(5):500-5.
    View in: PubMed
    Score: 0.006
  39. An inducible caspase 9 safety switch can halt cell therapy-induced autoimmune disease. J Immunol. 2008 May 01; 180(9):6365-73.
    View in: PubMed
    Score: 0.006
  40. Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes. Blood. 2007 Oct 15; 110(8):2793-802.
    View in: PubMed
    Score: 0.006
  41. Regression of experimental medulloblastoma following transfer of HER2-specific T cells. Cancer Res. 2007 Jun 15; 67(12):5957-64.
    View in: PubMed
    Score: 0.005
  42. Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease. Blood. 2007 Oct 01; 110(7):2620-30.
    View in: PubMed
    Score: 0.005
  43. Dendritic cell function after gene transfer with adenovirus-calcium phosphate co-precipitates. Mol Ther. 2007 Feb; 15(2):386-92.
    View in: PubMed
    Score: 0.005
  44. T lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells. Blood. 2006 Dec 01; 108(12):3890-7.
    View in: PubMed
    Score: 0.005
  45. Assessing the safety of cytotoxic T lymphocytes transduced with a dominant negative transforming growth factor-beta receptor. J Immunother. 2006 May-Jun; 29(3):250-60.
    View in: PubMed
    Score: 0.005
  46. An inducible caspase 9 safety switch for T-cell therapy. Blood. 2005 Jun 01; 105(11):4247-54.
    View in: PubMed
    Score: 0.005
  47. Human telomerase reverse transcriptase-specific T-helper responses induced by promiscuous major histocompatibility complex class II-restricted epitopes. Clin Cancer Res. 2003 Oct 15; 9(13):4743-55.
    View in: PubMed
    Score: 0.004
  48. Induction of vigorous helper and cytotoxic T cell as well as B cell responses by dendritic cells expressing a modified antigen targeting receptor-mediated internalization pathway. J Immunol. 2000 Oct 15; 165(8):4581-91.
    View in: PubMed
    Score: 0.003
  49. Autoimmune disease induced by dendritic cell immunization against leukemia. Leuk Res. 1999 Jun; 23(6):549-57.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.